BriaCell Therapeutics Corp.
BCT.TO
TSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.12% | 5.51% | -2.92% | -4.82% | -7.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.52% | 48.31% | -31.43% | -27.06% | -39.40% |
| Operating Income | -61.52% | -48.31% | 31.43% | 27.06% | 39.40% |
| Income Before Tax | -42.01% | -553.76% | -467.86% | 44.08% | -197.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.01% | -553.76% | -467.86% | 44.08% | -197.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 198.15% | 110.12% | 317.02% | 18.07% | -36.53% |
| Net Income | -41.28% | -566.40% | -457.09% | 44.30% | -196.68% |
| EBIT | -61.52% | -48.31% | 31.43% | 27.06% | 39.40% |
| EBITDA | -61.84% | -49.73% | 31.70% | 27.30% | 39.69% |
| EPS Basic | 86.68% | 9.46% | -201.85% | 78.02% | -158.00% |
| Normalized Basic EPS | 86.58% | 7.74% | -200.05% | 78.07% | -157.59% |
| EPS Diluted | 86.68% | 9.34% | -201.87% | 78.02% | 56.14% |
| Normalized Diluted EPS | 86.58% | 7.74% | -200.05% | 78.07% | -160.09% |
| Average Basic Shares Outstanding | 960.75% | 635.82% | 250.80% | 153.52% | 66.76% |
| Average Diluted Shares Outstanding | 960.75% | 635.82% | 250.80% | 153.52% | 59.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |